Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Viking Therapeutics stock last closed at $23.94, up 1.44% from the previous day, and has decreased 63.98% in one year. It has overperformed other stocks in the Biotechnology industry by 0.15 percentage points. Viking Therapeutics stock is currently +26.53% from its 52-week low of $18.92, and -70.75% from its 52-week high of $81.86.
As of Apr 17, 2025, there are 112.25M VKTX shares outstanding. The market value of VKTX is $2.69B. In the last 24 hours, 5.04M VKTX shares were traded.
How to Buy Viking Therapeutics Stock
Not sure how to invest in Viking Therapeutics stock? Here's how.
Decide where to buy Viking Therapeutics stock: You need to decide on a stock brokerage, but don't worry - we've tried dozens of online brokerages and apps to help you determine where to buy Viking Therapeutics stock.
Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
Fund your investment account: Select your payment method and add your information.
Evaluate Viking Therapeutics stock: The Viking Therapeutics ticker symbol is VKTX. Is Viking Therapeutics stock a good investment? Should you buy shares of VKTX? How do VKTX's underlying business fundamentals look? Do top analysts think Viking Therapeutics is a good buy? Why has VKTX's stock price moved recently? (Hint: Our stock market research website can help you decide if VKTX is a good stock to buy).
Place your VKTX purchase: Decide if you will purchase VKTX shares at the current market price or use a limit order to buy VKTX stock at a given price.
Get notifications regarding your investment in VKTX: Create a watchlist to watch your new investment in Viking Therapeutics stock.
Step 1: Decide where to buy Viking Therapeutics stock
You will need an online brokerage account in order to access the NASDAQ market and buy VKTX shares.
A brokerage account enables you to buy and sell a number of investments, such as stocks, bonds, mutual funds, and ETFs.
Our preferred brokerage: eToro
Based on our experience, eToro is the best stock brokerage. eToro gives you:
Invest in stocks with zero commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
Access to global markets: From Tech to Healthcare, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
Social investing: eToro offers a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by creating an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Create a brokerage account
Now that you've selected the right brokerage, you need to fill out some personal details so you can buy VKTX today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Evaluate Viking Therapeutics stock
Once you have chosen the best place to buy Viking Therapeutics stock, it's crucial to evaluate their stock before you invest, so you truly understand the risk and opportunity.
Viking Therapeutics stock quick numbers
VKTX Price
$23.94
1w %
11.25%
1y %
-63.98%
5y %
325.98%
P/E
-23.7x
P/B
3.05x
P/S
N/A
PEG
N/A
Revenue
$0.00
Earnings
-$109.96M
Fore. Rev. Growth
N/A
Fore. Earn. Growth
N/A
Market Cap
$2.69B
Next Earnings
Apr 22, 2025
Next Dividend
N/A
Fundamentals of VKTX
WallStreetZen was created to help part-time investors do more in-depth fundamental analysis.
VKTX has $902.66M in cash and short term investments. This is enough to cover its annual cash burn of $87.79M.
VKTX has cash burn of 87790000. It has sufficient cash and short-term investments to cover this for at least one year.
There are more short-term assets than long-term liabilities on the VKTX balance sheet.
VKTX has a low debt to equity ratio of 0.03.
There are more short-term assets than short-term liabilities on the VKTX balance sheet.
Cons:
Total VKTX debt is higher than 5 years ago, relative to shareholder equity.
Do Wall Street analysts think it's a good time to buy VKTX stock
Out of 8 Equities analysts who monitor VKTX, the consensus analyst rating on VKTX is a Strong Buy
It's important to note that analyst forecasts are not recommendations, nor are they financial advice.
Most Recent VKTX Analyst Forecasts
Mayank Mamtani, a top 4% analyst from B. Riley Securities reiterates VKTX with a strong buy rating and lowers their VKTX price target from $109.00 to $96.00, on Feb 7, 2025.
Steven Seedhouse, a top 15% analyst from Raymond James maintains VKTX with a strong buy rating and raises their VKTX price target from $122.00 to $125.00, on Feb 6, 2025.
Raymond James's Steven Seedhouse raised their price target on Viking Therapeutics (NASDAQ: VKTX) by 2.5% from $122 to $125 on 2025/02/06. The analyst maintained their Strong Buy rating on the stock.
Attributing their price target hike on Viking Therapeutics to the company's "programs that provide a comprehensive approach to treating a broad range of obesity patients," Seedhouse detailed:
The two Phase 3 subQ VK2735 studies in obese and obese+T2DM patients are now expected to be initiated in Q22025.
The Phase 2 oral VK2735 Phase 2a study evaluating six dosing cohorts against a placebo over 13 weeks is enrolling as planned with topline readout expected in 2H 2025.
And, the company provided some additional details to a maintenance therapy study that will evaluate the potential for daily oral dosing and monthly subQ dosing after 4 weeks of rapid titration to high-dose subQ treatment.
Biren Amin, a bottom 4% analyst from Piper Sandler maintains VKTX with a strong buy rating and lowers their VKTX price target from $74.00 to $71.00, on Feb 6, 2025.
No, Viking Therapeutics doesn't provide an income stream by paying out dividends.
What do other traders have to say about VKTX?
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Place your VKTX purchase
There are two main order types:
Market order: A market order is an order to buy or sell a stock at the best possible price. Market orders are mostly the best for newer investors.
Limit order: A limit order enables you to buy or sell a stock at a specific price (or better). If you want to ensure you're buying or selling at a specific dollar amount, place a limit order.
Hit the Open button and your broker will execute the order.
If you require additional assistance buying stocks on eToro, click the how to video below:
How much does it cost to buy one Viking Therapeutics share?
As of Apr 17, 2025, it costs $23.94 to buy one share of Viking Therapeutics stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.418 shares of VKTX.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.